Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards

Disease

Therapeutic or Technology

Disease	Cell Type	Therapeutic or Technology	Institution	Project Objective
Muscle Injury	Adult Stem Cell	Personalized cell therapy	UCSF	Development Candidate, Proof of Concept
Muscular Dystrophy	Embryonic Stem Cell	Protein/peptide therapy	Juvena Therapeutics Inc	Pre-IND/IDE or Equivalent
Neurological Disorders	iPS Cell	Gene Therapy, cell free	Navega Therapeutics	Development Candidate, Proof of Concept
Neurological Disorders, Sanfilippo Syndrome/MPS III	iPS Cell	Gene-modified, personalized cell therapy	UC Irvine	Development Candidate, Proof of Concept
Other	Adult Stem Cell	Protein/peptide therapy	Intact Therapeutics, Inc.	Development Candidate, Proof of Concept
Ovarian Cancer	Adult Stem Cell	Gene-modified, personalized cell therapy	COH	Development Candidate, Proof of Concept
Ovarian Cancer	iPS Cell	Gene-modified, donor cell therapy	UCSD	Development Candidate, Proof of Concept
Ovarian Cancer	Adult Stem Cell	Gene-modified, donor cell therapy	COH	Pre-IND/IDE or Equivalent
Pancreatic Cancer	Cancer Stem Cell	Small molecule therapy	UCSD	Development Candidate, Proof of Concept
Parkinson's Disease	Vital Research Opportunity	Gene Therapy, cell free	Brain Neurotherapy Bio	Clinical Trial, Phase 1 or Phase 1/2
Parkinson's Disease	Adult Stem Cell	Gene-modified, donor cell therapy	UCSF	IND
Pulmonary Hypertension, Vascular Disease	Adult Stem Cell	Donor cell therapy	Cedars-Sinai	Clinical Trial, Phase 1 or Phase 1/2
Retinitis Pigmentosa		Therapeutic Approach	jCyte	Clinical Trial, Phase 2
Retinitis Pigmentosa	Adult Stem Cell	Donor cell therapy	Cedars-Sinai	Clinical Trial, Phase 1 or Phase 1/2
Retinitis Pigmentosa	Other	Donor cell therapy	jCyte	Clinical Trial, Phase 2
Retinitis Pigmentosa	Embryonic Stem Cell	Donor cell therapy	UC Irvine	Pre-IND/IDE or Equivalent
Retinitis Pigmentosa	Somatic Cell	Gene Therapy, cell free	Ray Therapeutics, INC	Pre-IND/IDE or Equivalent
Sarcoma	Adult Stem Cell	Gene-modified, personalized cell therapy	Stanford	Development Candidate, Proof of Concept
Sarcoma	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	Clinical Trial, Phase 1 or Phase 1/2
Severe Combined Immunodeficiency, X-linked (X-SCID)	Adult Stem Cell	Antibody	Jasper Therapeutics, Inc.	Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCLA	Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	Boston Children's Hospital	Clinical Trial, Phase 2
Sickle Cell Disease	Adult Stem Cell	Donor cell therapy	COH	Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease	Adult Stem Cell	Gene-modified, personalized cell therapy	UCSF	IND
Sickle Cell Disease	Adult Stem Cell	Donor cell therapy	ExCellThera Inc.	Clinical Trial, Phase 1 or Phase 1/2
Solid Tumors			BioEclipse Therapeutics INC.	Clinical Trial, Phase 1 or Phase 1/2
Spina Bifida	Adult Stem Cell	Donor cell therapy	UC Davis	Clinical Trial, Phase 1 or Phase 1/2
Spinal Cord Injury	Embryonic Stem Cell	Donor cell therapy	UCSD	Pre-IND/IDE or Equivalent
Spinal Cord Injury	Embryonic Stem Cell	Gene-modified, donor cell therapy	UCSD	Development Candidate, Research Insights
Spinal Cord Injury	Adult Stem Cell	Donor cell therapy	UC Irvine	Pre-IND/IDE or Equivalent
Spinal Cord Injury	iPS Cell	Donor cell therapy	Stanford	Development Candidate, Proof of Concept
Stroke	Embryonic Stem Cell	Donor cell therapy	Stanford	Clinical Trial, Phase 1 or Phase 1/2
Stroke	iPS Cell	Donor cell therapy	UCLA	Pre-IND/IDE or Equivalent
Traumatic Brain Injury	Embryonic Stem Cell	Donor cell therapy	UC Irvine	Pre-IND/IDE or Equivalent
Traumatic Brain Injury	Embryonic Stem Cell	Exosomes based therapy	UC Irvine	Development Candidate, Proof of Concept, Research Insights
Traumatic Brain Injury	iPS Cell	Donor cell therapy	UC Irvine	Development Candidate, Research Insights
Type 1 diabetes	iPS Cell	Biologic	UCLA	Development Candidate, Proof of Concept
Type 1 diabetes	Embryonic Stem Cell	Gene-modified, donor cell therapy	Salk	Development Candidate, Proof of Concept
Type 1 diabetes	Embryonic Stem Cell	Gene-modified, donor cell therapy	Lundquist Institute	Development Candidate, Proof of Concept
Type 1 diabetes	Adult Stem Cell	Donor cell therapy	UCSF	Clinical Trial, Phase 1 or Phase 1/2
Type 1 diabetes	Embryonic Stem Cell	Donor cell therapy	ViaCyte	Clinical Trial, Phase 1 or Phase 1/2
Vascular Disease	Adult Stem Cell	Biologic	UCSD	Pre-IND/IDE or Equivalent
Wounds, ulcers		Small molecule therapy	UCLA	IND

California's Stem Cell Agency

California Institute for Regenerative Medicine

Active Awards Portfolio Dashboard

Filter Awards

Pages

aa Multiple Diseases (Centers & Resoures)
Aging
Arthritis
Blood Disorders
– Alpha Thalassemia Major
– Anemia
– Beta Thalassemia
– Bone Marrow Transplant and Viral Infection
– Hemophilia A
– Hyper IgM Syndrome
– IPEX Syndrome
– Leukocyte Adhesion Deficiency
– Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
– Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
– Severe Combined Immunodeficiency, X-linked (X-SCID)
– Sickle Cell Disease
– X-linked Chronic Granulomatous Disease
Bone or Cartilage Disease
– Cartilage defect
– Intervertebral disc degeneration
– Osteoarthritis
– Osteonecrosis
– Osteoporosis, malignant infantile
Cancer
– Blood Cancer
–– Acute Myeloid Leukemia
–– B cell cancers
–– HIV-related Lymphoma
–– Leukemia
–– Leukemia, Acute Myeloid (AML)
–– Multiple Myeloma
– Solid Tumors
–– Brain Cancer
–– Breast Cancer
–– Colon Cancer
–– Lung Cancer
–– Melanoma
–– Ovarian Cancer
–– Pancreatic Cancer
–– Prostate Cancer
–– Sarcoma
–– Skin cancer
Developmental Disorders
Fertility
Genetic Disorder
Hearing Loss
Heart Disease
– Heart disease associated with Duchenne muscular dystrophy
– Heart failure
– Pulmonary Hypertension
–– Hypertension, pulmonary arterial
Immune Disease
– Thymic Disorder, 22q11 Deletion/DiGeorge
Incontinence
Infectious Disease
– COVID-19
– HIV/AIDS
– Zika virus
Kidney Disease
– Kidney Failure
Metabolic Disorders
– Cystinosis
– Danon Disease
– Diabetes
–– Diabetic Wounds
–– Type 1 diabetes
– Intestinal Disease
–– Inflammatory bowel disease
– Liver Disease
– Sanfilippo Syndrome/MPS III
Multiple Indications (Alpha Clinics)
Neurological Disorders
– Alzheimer's Disease
– Amyotrophic Lateral Sclerosis
– Angelman Syndrome
– Autism
– Brain Injury, hypoxic, ischemic
– Canavan Disease
– Dementia
– Epilepsy
– Huntington's Disease
– Multiple Sclerosis
– Neuropathy
– Parkinson's Disease
– Rett's Syndrome
– Spina Bifida
– Spinal Cord Injury
– Spinal Muscular Atrophy
– Stroke
– Traumatic Brain Injury
Other
Pediatrics
Respiratory Disorders
– Cystic Fibrosis
– Lung Disease, Fibrosis
Skeletal/Smooth Muscle disorders
– Bladder or Urinary Tract Disorder
– Duchenne Muscular Dystrophy
– Muscle Injury
– Muscular Dystrophy
Skin Disease
– Epidermolysis Bullosa
– Wounds, ulcers
Toxicity
Trauma
Vascular Disease
Vision Loss
– Age-related macular degeneration
– Corneal Damage
– Retinitis Pigmentosa

Therapeutic Approach
– Biologic
–– Antibody
–– Convalescent Plasma
–– Exosomes based therapy
–– Gene modification
–– Nucleic acid based therapy
–– Protein/peptide therapy
–– Vaccine
– Gene Therapy (All)
–– Gene Therapy, cell free
–– Gene-modified, donor cell therapy
–– Gene-modified, personalized cell therapy
– Small molecule therapy
– Device
– Donor cell therapy
– Personalized cell therapy
– Other Components
Technology
– Assay development
– Cell Line Generation-Resource
– Diagnostic Test
– Gene editing tools
– Cell delivery or targeting
– Cell imaging & tracking
– Cell processing & handling
– Exploring disease mechanisms
– Exploring stem cell mechanisms
– Immune tolerance/management
– Model system development
– Specific Cell Type Derivation
– Therapeutic target discovery
– Tissue engineering